Cited 22 time in
Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Hamada, Tsuyoshi | - |
| dc.contributor.author | Liu, Li | - |
| dc.contributor.author | Nowak, Jonathan A. | - |
| dc.contributor.author | Mima, Kosuke | - |
| dc.contributor.author | Cao, Yin | - |
| dc.contributor.author | Ng, Kimmie | - |
| dc.contributor.author | Twombly, Tyler S. | - |
| dc.contributor.author | Song, Mingyang | - |
| dc.contributor.author | Jung, Seungyoun | - |
| dc.contributor.author | Dou, Ruoxu | - |
| dc.contributor.author | Masugi, Yohei | - |
| dc.contributor.author | Kosumi, Keisuke | - |
| dc.contributor.author | Shi, Yan | - |
| dc.contributor.author | da Silva, Annacarolina | - |
| dc.contributor.author | Gu, Mancang | - |
| dc.contributor.author | Li, Wanwan | - |
| dc.contributor.author | Keum, NaNa | - |
| dc.contributor.author | Wu, Kana | - |
| dc.contributor.author | Nosho, Katsuhiko | - |
| dc.contributor.author | Inamura, Kentaro | - |
| dc.contributor.author | Meyerhardt, Jeffrey A. | - |
| dc.contributor.author | Nevo, Daniel | - |
| dc.contributor.author | Wang, Molin | - |
| dc.contributor.author | Giannakis, Marios | - |
| dc.contributor.author | Chan, Andrew T. | - |
| dc.contributor.author | Giovannucci, Edward L. | - |
| dc.contributor.author | Fuchs, Charles S. | - |
| dc.contributor.author | Nishihara, Reiko | - |
| dc.contributor.author | Zhang, Xuehong | - |
| dc.contributor.author | Ogino, Shuji | - |
| dc.date.accessioned | 2023-04-28T06:42:03Z | - |
| dc.date.available | 2023-04-28T06:42:03Z | - |
| dc.date.issued | 2018-11 | - |
| dc.identifier.issn | 0959-8049 | - |
| dc.identifier.issn | 1879-0852 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/8935 | - |
| dc.description.abstract | Background: High-level plasma 25-hydroxyvitamin D[25(OH)D] has been associated with lower colorectal cancer incidence and mortality. Considering evidence indicating immunomodulatory effects of vitamin D, we hypothesised that survival benefits from high systemic vitamin D level might be stronger for colorectal carcinoma with lower immune response to tumour. Methods: Using 869 colon and rectal cancer cases within the Nurses' Health Study and Health Professionals Follow-up Study, we assessed the prognostic association of postdiagnosis 25(OH) D score [derived from diet and lifestyle variables to predict plasma 25(OH) D level] in strata of levels of histopathologic lymphocytic reaction. The Cox proportional hazards regression model was adjusted for potential confounders, including microsatellite instability, CpG island methylator phenotype, LINE-1 methylation, PTGS2 (cyclooxygenase-2) expression and KRAS, BRAF and PIK3CA mutations. Results: The association of postdiagnosis 25(OH) D score with colorectal cancer-specific mortality differed by levels of peritumoural lymphocytic reaction (p(interaction) = 0.001). Multivariable-adjusted mortality hazard ratios for a quintile-unit increase of 25(OH) D score were 0.69 [95% confidence interval (CI), 0.54-0.89] in cases with negative/low peritumoural lymphocytic reaction, 1.08 (95% CI, 0.93-1.26) in cases with intermediate peritumoural reaction and 1.25 (95% CI, 0.75-2.09) in cases with high peritumoural reaction. The survival association of the 25(OH) D score did not significantly differ by Crohn's-like lymphoid reaction, intratumoural periglandular reaction or tumour-infiltrating lymphocytes. Conclusions: The association between the 25(OH) D score and colorectal cancer survival is stronger for carcinomas with lower peritumoural lymphocytic reaction. Our results suggesting interactive effects of vitamin D and immune response may contribute to personalised dietary and lifestyle intervention strategies. (C) 2018 Elsevier Ltd. All rights reserved. | - |
| dc.format.extent | 10 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ELSEVIER SCI LTD | - |
| dc.title | Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1016/j.ejca.2018.07.130 | - |
| dc.identifier.scopusid | 2-s2.0-85053203682 | - |
| dc.identifier.wosid | 000447292100012 | - |
| dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF CANCER, v.103, pp 98 - 107 | - |
| dc.citation.title | EUROPEAN JOURNAL OF CANCER | - |
| dc.citation.volume | 103 | - |
| dc.citation.startPage | 98 | - |
| dc.citation.endPage | 107 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | sci | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Oncology | - |
| dc.relation.journalWebOfScienceCategory | Oncology | - |
| dc.subject.keywordPlus | IMMUNOTHERAPY | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordPlus | PROGNOSIS | - |
| dc.subject.keywordPlus | MORTALITY | - |
| dc.subject.keywordPlus | ASPIRIN | - |
| dc.subject.keywordPlus | RISK | - |
| dc.subject.keywordAuthor | Clinical outcome | - |
| dc.subject.keywordAuthor | Immunology | - |
| dc.subject.keywordAuthor | Molecular pathological epidemiology | - |
| dc.subject.keywordAuthor | Precision medicine | - |
| dc.subject.keywordAuthor | Tumour microenvironment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
